Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART-123 safety in mCRC patients receiving oxaliplatin and bevacizumab
NCT05251727Phase 1Terminated
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of thrombomodulin alfa in chemotherapy-induced peripheral neuropathy (CIPN) (6 arms), sponsored by Veloxis Pharmaceuticals. Primary endpoints: Treatment-emergent Adverse Events at 6 weeks, Serious Treatment-emergent Adverse Events at 6 weeks and 5 more. Started Mar 2022; status: terminated.
02
Drugs
thrombomodulin alfa
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05251727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251727.